Peptide Research and Development Company

159 6718 4799


发布时间:2023-05-26 16:59:50
0 家企业看过


Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-Eicosanedioic acid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 
     Tirzepatide, a weekly double agonist of glucose dependent insulin stimulating peptide (GIP, also known as gastric inhibitory peptide) receptor and pancreatic peptide-1 (GLP-1) receptor developed by Lilly. In May 2022, Tirzepatide, as a "first in class" drug, was approved by the US FDA for marketing. It is the first new generation diabetes drug launched in the past decade. Tilposide defeated Smeglutide in phase III clinical head-on trials and is bound to become a strong competitor in the field of hypoglycemic and weight loss.


no cache
Processed in 0.491017 Second.